# Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients

Study · id `cardio:ct-nct01069692` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01069692](<https://clinicaltrials.gov/study/NCT01069692>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01069692

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 115 participants.

## Technical summary

Registry record NCT01069692. Randomized; double masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2010-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 115 participants (enrolled count; ClinicalTrials.gov record NCT01069692, source copy `cardio:ctgov-nct01069692-2020-12-19`, retrieved 2026-10-26)
- Start date: 2010-02 (registry gives no type) (ClinicalTrials.gov record NCT01069692, source copy `cardio:ctgov-nct01069692-2020-12-19`, retrieved 2026-10-26)
- Primary completion: 2010-10 (actual) (ClinicalTrials.gov record NCT01069692, source copy `cardio:ctgov-nct01069692-2020-12-19`, retrieved 2026-10-26)
- Completion: Not reported
- Countries: Belgium; Italy (ClinicalTrials.gov record NCT01069692, source copy `cardio:ctgov-nct01069692-2020-12-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01069692-2020-12-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients
- Acronym: SBR759
- Condition: Hyperphosphatemia
- Condition: Chronic Kidney Disease
- Intervention (Drug): SBR759A
- Intervention (Drug): SBR759A
- Intervention (Drug): SBR759A
- Intervention (Drug): SBR759A
- Intervention (Drug): SBR759A
- Lead sponsor: Novartis
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy (`cardio:pubmed-23670305`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0948d17a058eb68a70078f1e2dcbd1be731ac7b6760a61af0191182919fc26d4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
